


page 1 of 2

JC13 Rec'd PCT/PTO 27 MAR 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 107089487		INTERNATIONAL APPLICATION NO. PCT/EP00/09356		ATTORNEY'S DOCKET NUMBER P/2107-210	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO 890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO 740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) 710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	17 - 20 =	0	X \$18.00	\$	
Independent claims	3 - 3 =	0	X \$4.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 890.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$ 890.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 890.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 890.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 890.00</u> to cover the above fees is enclosed. Check No. <u>8891</u> b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>15-0700</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 Avenue of the Americas New York, NY 10036-8403 Tel: (212) 382 0700					
				 SIGNATURE Charles C. Achkar NAME <u>43,311</u> REGISTRATION NUMBER	

PTO/PCT Rec'd 12 AUG 2002

#5

P/2107-210

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Florian GUNZER et al.

Date: August 12, 2002

Serial No.: 10/089,487

Int'l. Appln. No.: PCT/EP00/09356

Int'l. Filing Date: 26 September 2000

For: MULTIPLEX PCR FOR DETECTING EHEC INFECTIONS

Assistant Commissioner for Patents

"BOX SEQUENCE"

Washington, D.C. 20231

**SECOND PRELIMINARY AMENDMENT, SUBMISSION OF
SEQUENCE LISTING AND STATEMENT UNDER 37 C.F.R. §1.821(f)**

Sir:

In reply to the Notification to Missing Requirements dated June 12, 2002, a copy of which is enclosed, Applicants submit herewith a sequence listing for eight biological sequences disclosed in the above-identified patent application and amend the subject application as follows:

FEE CALCULATION

Any additional fee required has been calculated as follows:

_____ If checked, "Small Entity" status is claimed.

	NO. CLAIMS AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		EXTRA PRESENT		RATE	ADDIT. FEE
TOTAL	17	MINUS	20	* =	0	X	(\$9 SE or \$18)	\$ 0.00
INDEP.	3	MINUS	3	** =	0	X	(\$40 SE or \$80)	\$ 0.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						X	(\$135 SE or \$270)	\$ 0.00
* not less than 20		** not less than 3					TOTAL \$	0.00

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

AMENDMENTS

 X If checked, amendment(s) to the specification and/or claims are submitted herewith.

1. If checked, an abstract is submitted as the last page of Appendix A.

2. Specification:

Please replace original pages 22-23 of the specification with substitute pages 22-23 attached hereto under 37 C.F.R. §1.96(b)(2)(ii). Entry is respectfully requested.

REMARKS

A copy of the sequence listing in computer readable form is also enclosed. The content of enclosed paper and computer readable copies of the sequence listing are the same, and the submission contains no new matter.

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee (mail label #EM023991666US) in an envelope addressed to: Assistant Commissioner for Patents, Box PCT (DO/EO/US), Washington, D.C. 20231, on August 12, 2002:

Dorothy Jenkins

Name of Person Mailing Correspondence

Dorothy Jenkins

Signature

August 12, 2002

Date of Signature

RCF/CCA:lac

Respectfully submitted,

Charles C. Achkar

Charles C. Achkar

Registration No.: 43,311

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

PTO/PCT Rec'd 12 AUG 2002

#5

- 22 -

SEQUENCE LISTING

<110> Gunzer, Florian
Bellin, Tobias

<120> Multiplex PCR for Detecting EHEC Infections

<130> P/2107-210

<140> 10/089,487

<141> 2002-08-12

<150> PCT/EP00/09356

<151> 2000-09-26

<150> DE 199 46 296.8

<151> 1999-09-28

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 24

<212> DNA

<213> Escherichia coli

<400> 1

agtcgtacgg ggatgcagat aaat

24

<210> 2

<211> 24

<212> DNA

<213> Escherichia coli

<400> 2

ccggacacat agaaggaaac tcat

24

<210> 3

<211> 20

<212> DNA

<213> Escherichia coli

<400> 3

ttccggaatg caaatcagtc

20

```
<400>      8
agcagaagcc ttacgcttca ggc                                     23
```

P/2107-210

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Florian GUNZER et al

Date: March 27, 2002

Serial No.:

Group Art Unit:

Filed:

Examiner:

For: MULTIPLEX PCR FOR DETECTING EHEC INFECTIONS

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Attn: Box PCT (US/DO/EO)

AMENDMENT/SUBMISSION

Prior to examination, please amend the application as follows.

FEE CALCULATION

Any additional fee required has been calculated as follows:

_____ If checked, "Small Entity" status is claimed.

	NO. CLAIMS AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		EXTRA PRESENT		RATE	ADDIT. FEE
TOTAL	17	MINUS	20	* =	0	X	(\$9 SE or \$18)	\$
INDEP.	3	MINUS	3	** =	0	X	(\$42 SE or \$84)	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						X	(\$140 SE or \$280)	\$
* not less than 20 ** not less than 3								TOTAL \$ -----

If any additional payment is required, a check which includes the calculated fee of \$ _____
(OFGS Check No. _____) is attached.

In the event the actual fee is greater than the payment submitted or is inadvertently not
enclosed or if any additional fee during the prosecution of this application is not paid, the Patent
Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

AMENDMENTS

☒ If checked, amendment(s) to the specification and/or claims are submitted herewith.

1. Claims:

Please amend claims 4, 6, 8, 10, 13, 14 and 17 pursuant to 37 C.F.R. § 1.121(c)(i) as set forth in the “clean” version attached hereto as Appendix A. Entry is respectfully requested. A version with markings to show the changes made pursuant to 37 C.F.R. § 1.121(c)(ii) is attached hereto as Appendix B.

☐ If checked, the optional complete set of “clean” claims pursuant to 37 C.F.R. § 1.121(c)(3) is attached hereto as Appendix C.

REMARKS/ARGUMENT

This Preliminary Amendment is being submitted to change the multiple dependent claims to single dependent claims in order to eliminate the improper multiple dependent claims and to reduce the government filing fee.

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label # EL924372505US) in an envelope addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on March 27, 2002:

Dorothy Jenkins


Name of Person Mailing Correspondence


Signature

March 27, 2002

Date of Signature

Respectfully submitted,


Charles C. Achkar
Registration No.: 43,311
OSTROLENK, FABER, GERB & SOFFEN, LLP
1180 Avenue of the Americas
New York, New York 10036-8403
Telephone: (212) 382-0700

APPENDIX A
“CLEAN” VERSION OF EACH PARAGRAPH/SECTION/CLAIM
37 C.F.R. § 1.121(b)(ii) AND (c)(i)

CLAIMS (with indication of amended or new):

(Amended) 4. A method as claimed in claim 2, characterized in that the product of the amplification reaction is additionally detected by hybridization.

(Amended) 6. The method as claimed in claim 2, characterized in that the amplification product is detected with the aid of fluorescence detection.

(Amended) 8. The method as claimed in claim 4, characterized in that the amplification product is detected with the aid of fluorescence resonance energy transfer.

(Amended) 10. The method as claimed in claim 8, characterized in that human-pathogenic stxA2 and swine-pathogenic stxA2e are distinguished by means of a melting curve analysis.

(Amended) 13. The method as claimed in claim 9, characterized in that hybridization probes with sequences as shown in SEQ ID No. 5-8 or SEQ ID No. 8 are used.

(Amended) 14. Use of hybridization probes as claimed in claim 11 for determining melting curves.

(Amended) 17. A kit as claimed in claim 15, comprising reagents for amplifying additional pathogenicity factors.

APPENDIX B
VERSION WITH MARKINGS TO SHOW CHANGES MADE
37 C.F.R. § 1.121(b)(iii) AND (c)(ii)

CLAIMS:

4. A method as claimed in claim 2 [or 3], characterized in that the product of the amplification reaction is additionally detected by hybridization.
6. The method as claimed in claim [2-5] 2, characterized in that the amplification product is detected with the aid of fluorescence detection.
8. The method as claimed in claim [4-6] 4, characterized in that the amplification product is detected with the aid of fluorescence resonance energy transfer.
10. The method as claimed in claim 8 [or 9], characterized in that human-pathogenic stxA2 and swine-pathogenic stxA2e are distinguished by means of a melting curve analysis.
13. The method as claimed in claim 9 [or 10], characterized in that hybridization probes with sequences [as given in claim 11 or 12] as shown in SEQ ID No. 5-8 or SEQ ID No. 8 are used.
14. Use of hybridization probes as claimed in claim 11 [or 12] for determining melting curves.
17. A kit as claimed in claim 15 [or 16], comprising reagents for amplifying additional pathogenicity factors.

ART 34 AMDT

04-12-2001

Rec'd PCT/PTO 27 MAR 2002

10089487.001202

10/089487

EP0009356

- 1 -

Cytonet GmbH & Co. KG

PCT/EP00/09356

Multiplex PCR for detecting EHEC infections

The present invention originates from the diagnostic area of the detection of hemorrhagic diarrheal diseases.

Enterohemorrhagic E. coli pathogens (EHEC) are dangerous pathogens of diarrheal diseases which may be transmitted both by foodstuffs and by smear infections. Enterohemorrhagic E. coli organisms are able to form highly potent cytotoxins. These are proteins which have great similarity with the Shiga toxin of Shigella dysenteriae type 1 and are therefore called Shiga toxin 1 and Shiga toxin 2. The genes coding therefor for the respective subunits A and B are referred to as stxA1 GenBank number M19473) and stxB1 GenBank number M19473) and stxA2 (GenBank number X07865) and stxB2 GenBank number X07865). Pathogenic E. coli strains may contain either one of the two Shiga toxin genes or else both. In addition, the pathogens may have further associated virulence factors such as EHEC intimin, EHEC hemolysin, EHEC catalase, EHEC serine protease and EHEC enterotoxin.

The diagnostic detection of EHEC is, because of the transmission routes and of the low infectious dose of about 10^2 - 10^3 organisms, important not only for those with acute disease but also in order to identify possible excretors or find other sources of infection. In the state of the art, EHEC

REPLACEMENT SHEET

04-12-2001

EP0009356

- 1a -

infections are detected by microbiological means using sorbitol McConkey selective agar plates or by means of toxin ELISAs. In addition, PCR detection methods exist and can be used to detect Shiga toxin gene sequences (for example Chen et al., Applied and Environmental Microbiology Vol. 64 No. 11, pp. 4210-4116, 1998; Gannon et al., Applied Environmental Microbiology, Vol. 58 No. 12, pp. 3809-3815, 1992; Pierard et al., Journal of Clinical Microbiology Vol. 36, No. 11, pp. 3317-3322,). However, the only methods currently used in routine diagnosis are those which amplify the sequence coding for the B subunit.

REPLACEMENT SHEET

ART 34 AMDT

- 2 -

sorbitol McConkey selective agar plates or by means of toxin ELISAs. In addition, PCR detection methods exist and can be used to detect Shiga toxin gene sequences (for example Chen et al., Applied and Environmental Microbiology Vol. 64 No. 11, pp. 4210-4116, 1998; Gannon et al., Applied Environmental Microbiology, Vol. 58 No. 12, pp. 3809-3815, 1992; Pierard et al., Journal of Clinical Microbiology Vol. 36, No. 11, pp. 3317-3322.). However, the only methods currently used in routine diagnosis are those which amplify the sequence coding for the B subunit.

Sequence analysis of the Shiga toxin genes from various isolates has shown that not only are the primary sequences of Shiga toxin 1 and Shiga toxin 2 different from one another, but that, in addition, different EHEC isolates in which Shiga toxin 2 can be detected immunologically also display different alleles in relation to the sequence of the corresponding gene. Thus, the only primer sequences suitable for diagnostic detection of Shiga toxin 2 are those which are directed against highly conserved regions within the Shiga toxin genes and thus are able to detect the sequences of all the alleles.

In addition to the classical diarrheal diseases caused by known human-pathogenic EHEC pathogens, there exist other diarrheal diseases with a similar clinical picture. It has likewise been possible to diagnose enterohemorrhagic pathogens as the cause of these diseases by tests with Vero cell cultures (Pierard et al., Lancet 338, p. 762, 1991;

10059407 1001202

ART 34 AMDT

04-12-2001

EP0009356

- 3 -

This object is achieved by a nucleic acid

REPLACEMENT SHEET

04-12-2001

EP0009356

- 4 -

amplification reaction for the detection of clinically relevant EHEC infections, with which it is possible simultaneously to identify stxA1 and stxA2 sequences which are derived both from human-pathogenic and from swine-pathogenic pathogens.

The invention thus relates to a method with which, in a multiplex amplification reaction for the detection of clinically relevant EHEC infections, both stxA1 and stxA2 sequences are amplified, and which is characterized in particular by amplification both of human-pathogenic stxA2 isoforms and of swine-pathogenic stxA2_e isoforms. In this connection, the term "multiplex amplification reaction" refers to PCR methods in which at least two different primer pairs are used, one primer pair being used to amplify stxA1 sequences and a second primer pair being used to amplify stxA2 sequences. The term "swine pathogen" is used within the scope of this application for pathogens which have a Shiga toxin gene stxA2_e (Weinstein et al., J. Bacteriol. 170, pp. 4223-4230, 1988), GenBank number: M21534) and primarily cause edema disease in swine, but may also lead to diarrheal diseases and extraintestinal disease manifestations in humans.

Primers which have proved particularly suitable for carrying out the method of the invention have a length of 17-25 nucleotides, whose sequences is either identical to a

REPLACEMENT SHEET

ART 34 AMDT

04-12-2001

EP0009356

- 4a -

sequence as shown in SEQ ID No. 1-4, whose sequences represent continuous part-sequences of one of the sequences as shown in SEQ ID No. 1-4, or in which a sequence as shown in SEQ ID No. 1-4 forms a continuous part-sequence of the primer. The use of one, preferably more than one, particularly preferably all, of the primers of the invention for detecting EHEC infections is likewise an aspect of the invention.

Thus, multiplex amplification reactions in which either one, more than one or all of the primers of the invention are used have proved advantageous for detection of clinically relevant EHEC infections.

REPLACEMENT SHEET

- 5 -

as shown in SEQ ID No. 1-4, or in which a sequence as shown in SEQ ID No. 1-4 forms a continuous part-sequence of the primer. The use of one or more of the primers of the invention for detecting EHEC infections is likewise an aspect of the invention.

Thus, multiplex amplification reactions in which either one, more than one or all of the primers of the invention are used have proved advantageous for detection of clinically relevant EHEC infections.

The primers ordinarily used are chemically synthesized deoxyribonucleotides. However, it is also possible in principle to employ other nucleic acid molecules or their derivatives such as, for example, PNA (peptide nucleic acids). In addition, primers of the invention can also be conjugated to detectable or immobilizable molecules.

In a specific embodiment of the method of the invention, the product of the amplification is, in order to increase the sensitivity of the assay, additionally detected by hybridization. The hybridization probes suitable for this purpose preferably have a length of 25-35 nucleotides. Chemically synthesized deoxyribonucleotides are likewise ordinarily used, but may optionally be replaced by other nucleic acid molecules or their derivatives such as, for example, PNA (peptide nucleic acids). By definition, these probes are conjugated to a detectable label. This may be, for example, a fluorescent dye, an enzyme, a radioactive atom or a group detectable by mass spectrometry.

- 6 -

The invention therefore likewise relates to hybridization probes having a sequence or part-sequence as shown in SEQ ID No. 5-8. However, it has proved to be advantageous if a hybridization probe has a sequence which is identical or complementary to a region of the *stxA1* gene or of the *stxA2* gene which corresponds to the enzymatically active site of the polypeptide chain encoded by these genes. In the sequence of *stxA2*, this active site is located at nucleotide position 803-805 (Jackson et al, J. Bacteriol. 172, pp. 3346-3350, 1990). Hybridization probes having a sequence or part-sequence as shown in SEQ ID No. 8 are thus particularly preferred.

In a further particular embodiment, the multiplex amplification products obtained according to the invention are detected by means of fluorescence detection. Given the choice of a suitable fluorescent agent, it can be added even to the PCR mixture without impairing the amplification efficiency. This can take place, for example, by carrying out the PCR reaction in the presence of a fluorescent compound which, on binding to double-stranded DNA molecules and on excitation with light of a suitable wavelength, emits fluorescent signals (WO 97/46707):

The invention thus also relates to a method in which the multiplex amplification products are detected with the aid of a compound which fluoresces on binding to double-stranded DNA. For example, the fluorescent dye SybrGreen can be employed for a method of this type (WO 97/46714).

- 7 -

The present invention further relates to a method in which the stx sequences are detected with the aid of one or more fluorescence-labeled hybridization probes. Various embodiments are possible in this case, such as, for example, the use of molecular beacons (WO 95/13399, US patent No. 5 118 801) or so-called TaqMan probes (WO 96/34983).

Also suitable for the quantitative detection of nucleic acids are hybridization probes labeled with fluorescent dyes, such as, for example, oligonucleotides whose binding to a nucleic acid target can be detected by the principle of fluorescence resonance electron transfer (FRET) (WO 97/46707). This entails a so-called donor component, for example fluorescein, being excited with light of a particular wavelength. If a suitable acceptor component, such as, for example, certain rhodamine derivatives, is in the proximity, then resonance energy transfer to the acceptor component takes place, so that the acceptor molecule emits light of a particular emission wavelength.

The hybridization probes can be labeled by standard methods at the 5' end, at the 3' end or else internally. In a preferred embodiment, the various dyes are bound to two different hybridization probes which are able to hybridize in proximity onto the target nucleic acid. When in this embodiment both hybridization probes are bound to the target DNA, then both components of the FRET system are also in mutual proximity, so that fluorescence resonance energy transfer can be measured. This makes indirect quantification

- 8 -

of the target DNA possible.

The two oligonucleotide probes can moreover hybridize onto the same strand of the target nucleic acid, in which case one dye is preferably located on the 3'-terminal nucleotide of the first probe, and the other dye is preferably located on the 5'-terminal nucleotide of the second probe, so that the distance between the two is only a small number of nucleotides, and this number can be between 0 and 30. On use of fluorescein in combination with a rhodamine derivative such as, for example, LC-RED 640 or LC-RED 705 (Roche Molecular Biochemicals) it has emerged that the distances are advantageously from 0-15, in particular 1-5, nucleotides and, in many cases, one nucleotide. While maintaining the nucleotide distances between the dye components it is also possible to use probes which are conjugated not terminally but internally to one of the dyes. In the case of double-stranded target nucleic acids it is also possible to employ probes which bind to different strands of the target, as long as a particular nucleotide distance of 0 to 30 nucleotides is maintained between the two dye components.

Methods of the invention which have accordingly proved to be particularly advantageous are those in which stxA1 and stxA2 are detected with the aid of fluorescence resonance energy transfer. The invention likewise relates to hybridization probes having a sequence or part-sequence as shown in SEQ ID No. 5-8 and to methods in which these

- 9 -

specific hybridization probes are employed for the detection of clinically relevant EHEC infections.

A specific embodiment of the invention is thus also represented by fluorescence-labeled probe pairs either as shown in SEQ ID No. 5 and 6 or as shown in SEQ ID No. 7 and 8, which are advantageously labeled with, in each case, a FRET donor component such as, for example, fluorescein and with a FRET acceptor component such as, for example, Cy5, LC-RED 640, LC-RED 705 or another rhodamine derivative. Correspondingly labeled oligonucleotide combinations are referred to hereinafter as "FRET pairs".

It has proved particularly advantageous to use such FRET pairs for detecting amplification products during or after a multiplex amplification reaction. In a particular embodiment, one of the two amplification primers can at the same time be labeled with one of the two dyes employed, and thus contribute one of the two components of the FRET.

The use of suitable FRET pairs for detecting multiplex amplification products makes parallel, so-called real-time monitoring of PCR reactions possible, it being possible to find data for generating the amplification product as a function of the number of reaction cycles completed. This usually takes place by the oligonucleotides of the FRET pair also hybridizing onto the target nucleic acid because of the reaction and temperature conditions during the necessary annealing of the amplification primers onto the nucleic acid to be detected, and an appropriately

ART 34 ANDT

10089487 .081202

04-12-2001

- 10 -

EP0009356

product as a function of the number of reaction cycles completed. This usually takes place by the oligonucleotides of the FRET pair also hybridizing onto the target nucleic acid because of the reaction and temperature conditions during the necessary annealing of the amplification primers onto the nucleic acid to be detected, and an appropriately

REPLACEMENT SHEET

04-12-2001

EP0009356

- 10a -

measurable fluorescence signal being emitted with suitable excitation. It is thus possible on the basis of the data obtained to determine quantitatively the amount of target nucleic acid originally employed.

In another, preferred embodiment, the multiplex amplification products are detected after completion of the amplification reaction, in which case, after hybridization of the FRET pair onto the target nucleic acid to be detected, the temperature is increased continuously in a melting curve analysis. At the same time, the emitted fluorescence is measured as a function of the temperature and, in this way, a melting temperature at which the FRET pair employed no longer hybridizes onto the sequence to be detected is determined. If there are mismatches between the FRET pair employed and the amplification product, the melting point is significantly depressed. It is possible in this way to identify with one FRET pair different target nucleic acids whose sequences differ from one another slightly through one or a few point mutations.

This principle is employed according to the invention in a multiplex amplification reaction for detecting EHEC infections, in which there is use of an internal standard which differs from the stxA1 or stxA2 wild-type sequence (GeneBank number X07865) only in one or two point mutations. It is thus possible to distinguish amplified target nucleic acid and amplified internal standard from one another with

REPLACEMENT SHEET

ART 34 AMDT

10059437 .051202

04-12-2001

EP0009356

- 10b -

the aid of a melting curve analysis.

In this case, the standard is preferably employed only in small amounts of about 100 plasmid copies (1.7×10^{-22} mol), so that a positive signal relating to amplification of the internal standard not only indicates that the PCR has not been inhibited in any way in the particular mixture, but also represents a check of the sensitivity of the reaction.

REPLACEMENT SHEET

- 11 -

In this case, the standard is preferably employed only in small amounts of about 100 plasmid copies (1.7×10^{-22} mol), so that a positive signal relating to amplification of the internal standard not only indicates that the PCR has not been inhibited in any way in the particular mixture, but also represents a check of the sensitivity of the reaction.

A further aspect of the method of the invention relates to distinguishing human-pathogenic stxA2 and swine-pathogenic stxA2_e with the aid of the described melting curve analysis.

The use of FRET pairs as shown in SEQ ID No. 5 and 6 or 7 and 8 for determining melting curves or for distinguishing human-pathogenic stx and swine-pathogenic stx is in this connection likewise an aspect of the invention. This preferably entails use of a FRET pair as shown in SEQ ID No. 7 and 8.

The present invention additionally relates to kits which comprise various reagents for carrying out the methods of the invention. Such kits of the invention usually comprise amplification primers for carrying out a multiplex PCR as shown in SEQ ID No. 1-4. These kits may preferably also comprise hybridization probes, for example with sequences as shown in SEQ ID No. 5-8.

Furthermore, these kits may additionally comprise according to the invention primers and hybridization probes for amplification of DNA of one or more additional EHEC

- 12 -

virulence factors such as, for example, EHEC intimin, EHEC hemolysin, EHEC catalase, EHEC serine protease and EHEC enterotoxin. Finally, all the kits of the invention may additionally comprise reagents which are generally suitable for carrying out nucleic acid amplification reactions. These are preferably, but not exclusively, special buffers, Taq polymerase and deoxyribonucleotides.

Brief description of the figures:

Figures 1 and 2 show a melting curve analysis as described in example 2. The first derivative of the measured fluorescence is in each case depicted as a function of the respective temperature, measured with a FRET pair composed of fluorescein and LC-RED 640 for detecting stxA1 (figure 1) and a FRET pair composed of fluorescein and LC-RED 705 for detecting stxA2 (figure 2).

Example 1: DNA isolation from bacterial cultures and stool samples

Bacterial cultures were worked up after overnight culture in TSB broth (casein peptone, pancreatin digest 17.0 g/l; soy meal peptone, papain digest 3.0 g/l; sodium chloride 5.0 g/l; dipotassium hydrogen phosphate 2.5 g/l; glucose 2.5 g/l) with the aid of a commercial DNA extraction method (QIAamp DNA Mini Kit, Qiagen, Catalog No. 51304). For this purpose, 200 µl of the bacterial suspension were incubated with 20 µl of proteinase K and 200 µl of ATL buffer

- 13 -

at 56°C for 10 min. 200 µl of 96% ethanol were then admixed with the suspension. The solution was then put onto a QIAamp spin column and centrifuged at 6 000 g for 1 min. The columns were then washed once with 500 µl each of AW1 and AW2 buffers (bench centrifuge 20 000 g). After the second washing step, the column was centrifuged until dry once. The purified DNA was subsequently eluted with 200 µl of AE buffer (10 mM Tris/HCC 0.5 m MEDT A pH 9.0). Before use in the PCR reaction, the DNA concentration and purity were determined in a photometer (spectrum from 260 nm to 320 nm). A maximum of 500 ng of template DNA were employed for each PCR mixture. In background investigations, a DNA equivalent to 10^7 bacteria (corresponds to about 55 ng of DNA) was employed.

PCR investigations were carried out directly on stool samples using a special stool kit (QIAamp DNA Stool Kit, containing the same buffers as the QIAamp DNA Mini Kit). For this purpose, 200 mg of stool (200 µl in the case of diarrheal stools) were thoroughly mixed with 600 µl of ASL buffer. In parallel with this, 300 mg of matrix AX (adsorbent for inhibitors in stool samples) are resuspended in 900 µl of the same buffer. This suspension was then added to the dissolved stool sample and thoroughly mixed. Subsequently, the homogenate was incubated at 70°C for 5 min. The matrix AX and undissolved stool particles were then pelleted by a centrifugation step at 20 000 g for 3 min. 200 µl of the supernatant were then mixed in analogy to the above-mentioned QIAamp DNA mini protocol with 20 µl of proteinase K and

- 14 -

likewise incubated at 56°C for 10 min. Subsequently, entirely in analogy to the procedure for bacterial cultures, using the same buffers, the DNA was bound to a QIAamp spin column, washed, eluted and measured in a photometer. The same amounts of DNA as described above were employed in the subsequent PCR reaction.

Example 2: Amplification and identification of the amplification products

A multiplex PCR for detecting *stxA1* and *stxA2* in DNA isolated by one of the methods of example 1 was carried out in the LightCycler system (Roche Molecular Biochemicals) in accordance with the manufacturer's information. The amplification product was detected according to two different protocols either with the aid of SybrGreen as double-stranded DNA-binding agent or, alternatively, with the aid of FRET hybridization probes.

All the primers and hybridization probes used were HPLC-purified and were stored in stock solutions of 100 pM/ μ l (primers) or 3 pM/ μ l (probes). The primers employed were selected in this case so that it was possible to amplify a 418 bp fragment of *stxA1* (nucleotide position 598-1015, primers as shown in SEQ ID No. 1 and 2) and a 264 bp fragment of *stxA2* (nucleotide position 679-942, primers as shown in SEQ ID No. 3 and 4).

The hybridization probes employed for the detection were labeled by standard protocols. For detecting *stxA1*, an

- 15 -

oligonucleotide as shown in SEQ ID No. 5 was labeled at the 3' end with fluorescein and an oligonucleotide as shown in SEQ ID No. 6 was labeled at the 5' end. An oligonucleotide as shown in SEQ ID No. 7 was labeled at the 3' end with fluorescein and an oligonucleotide as shown in SEQ ID No. 8 was labeled at the 5' end with LC-RED 705 as hybridization probes for detecting stxA2.

Detection with SybrGreen:

2.0 µl of DNA master SYBR Green I (Roche Molecular Biochemicals, containing buffers, Taq DNA polymerase, dNTPs, MgCl₂ and SYBR Green I dye)

10 pM of each primer employed as shown in SEQ ID No. 1-4

2.4 µl of 25 mM MgCl₂ (working concentration 4 mM)

10 µl of DNA

20 µl complete mixture

Detection using hybridization probes:

2.0 µl of DNA master for hybridization probes (Roche Molecular Biochemicals, containing buffers, Taq polymerase, dNTPs and MgCl₂)

10 pM of each primer employed as shown in SEQ ID No. 1-4

3 pM of each hybridization probe employed as shown in SEQ ID No. 5 and 6 for stxA1 of SEQ ID No. 7 and 8 stxA2

2.4 µl of 25 mM MgCl₂ (final concentration 4 mM)

8.0 µl of DNA

20 µl complete mixture

Both mixtures were run with the same PCR program and terminated with a melting curve:

- 16 -

Temperature cycles:

95°C 120 sec denaturation at the start of the program
95°C 1 sec
55°C 5 sec (touchdown from 60°C to 55°C in 5 steps of 1°C)
72°C 20 sec
45 cycles

The melting curves were constructed after previous brief denaturation at 95°C in an interval from 50°C to 95°C in 0.2°C steps with continuous fluorescence measurement on channel 1 (SYBR Green), channel 2 (LC-Red 640) or channel 3 (LC-Red 705) with the aid of the LightCycler software 3.0.

In SYBR Green mode, the specificity of PCR products from stool samples was found via the melting point compared with a control of stx-positive bacteria, in particular in order to be able to distinguish the amplification product from nonspecific primer dimers. In addition, all the results were verified by gel electrophoresis.

In the case of the FRET hybridization probe format it was necessary to employ the color compensation file of the LightCycler 3.0 software to avoid crosstalk effects between channel 2 and 3. The results of a typical experiment are disclosed in figure 1 and 2:

Figure 1 shows the temperature dependence of the fluorescence from mixtures with different initial DNA concentrations in channel 2 (LC-RED 640) for detecting stxA1; figure 2 shows the fluorescence of the same samples measured in channel 3 (LC-RED 705) for detecting stxA2. In each case,

- 17 -

the first derivative of the fluorescence measured as a function of the particular melting curve temperature in accordance with the information from the LightCycler manufacturer is depicted. The temperatures of the curve maxima found thus correspond to the melting points of the respective hybridization probes.

Example 3: Sensitivity

DNA of the stx1 and stx2-positive E. coli strain EDL 933 was extracted and quantified by photometry as in example 1. Based on the assumption that 2×10^8 bacteria contain about 1 µg of DNA, the number of bacteria worked up was inferred and serial dilutions were set up. Cultured stool samples from routine diagnoses, which were free of intestinal pathogens, were processed by the method described above, as background. It was in this case possible to detect in multiplex mixtures as in example 2 equivalents of at least about 1.8 stx-positive bacteria in a background of about 1×10^7 stx-deficient bacteria in a reaction mixture.

Example 4: Specificity - detection of human- and swine-pathogenic EHEC

48 human isolates of various serotypes, whose genotype was unknown at the time of the invention but which had already been characterized as EHEC strains by other, prior art methods, were investigated as in example 2 in the FRET hybridization probe mode. In addition, 3 isolates from

- 18 -

pigs with E. coli edema disease were investigated. The result is shown in table 1:

Table 1: Detection of human- and swine-pathogenic stx						
Serial No.	Code No.	Source	Serotype	stx ₁	stx ₂	Tm stxA2
1	485/98	CI	O145:H ⁻	+	-	-
2	531/98	CI	O145:H ⁻	+	-	-
3	563/98	CI	O113:HNT	+	-	-
4	633/98	CI	O26:H ⁻	-	+	72°C
5	741/98	CI	O121:H ⁻	-	+	72°C
6	742/98	CI	O8:H ⁻	-	+	63°C
7	768/98	CI	O30:H21	-	+	72°C
8	802/98	CI	O157:H ⁻	-	+	72°C
9	1115/98	CI	O157:H ⁻	+	+	72°C
10	1168/98	CI	O128:H ⁻	+	+	63°C
11	1211/98	CI	O60:H ⁻	-	+	63°C
12	1244/98	CI	O6:H8	-	+	72°C
13	1273/98	CI	O6:H8	-	+	72°C
14	1295/98	CI	ONT:H ⁻	-	+	72°C
15	1306/98	CI	O157:H ⁻	+	+	72°C
16	1568/98	CI	O103:H ⁻	+	-	-
17	1613/98	CI	ONT:HNT	+	-	-
18	1695/98	CI	O103:H ⁻	+	-	-
19	1760/98	CI	O129:H ⁻	+	+	63°C
20	1762/98	CI	O129:H ⁻	+	+	63°C
21	1771/98	CI	O113:H2	+	+	63°C
22	54/99	CI	O103:H18	+	-	-
23	90/99	CI	O157:H ⁻	-	+	72°C
24	109/99	CI	O157:H ⁻	-	+	72°C
25	143/99	CI	O92:H32	-	+	63°C
26	144/99	CI	O92:H32	-	+	63°C
27	159/99	CI	O76:H ⁻	+	+	63°C
28	197/99	CI	O128:HNT	+	+	63°C
29	209/99	CI	ONT:HNT	-	+	72°C
30	240/99	CI	O30:HNT	-	+	72°C
31	285/99	CI	O145:HNT	+	-	-
32	363/99	CI	ONT:H ⁻	+	+	63°C
33	497/99	CI	O103:H4	+	-	-
34	516/99	CI	ONT:H ⁻	+	-	-

Table 1: Detection of human- and swine-pathogenic stx						
Serial No.	Code No.	Source	Serotype	stx ₁	stx ₂	T _m stxA2
35	575/99	CI	O157:H ⁻	-	+	72°C
36	576/99	CI	O157:H ⁻	-	+	72°C
37	594/99	CI	ONT:H ⁻	+	-	-
38	649/99	CI	ONT:H9	-	+	72°C
39	680/99	CI	O157:H ⁻	+	+	72°C
40	707/99	CI	ONT:HNT	+	+	63°C
41	713/99	CI	O115:H10	+	-	-
42	720/99	CI	O111:H ⁻	+	-	-
43	789/99	CI	O103:HNT	+	-	-
44	791/99	CI	O91:HNT	+	-	-
45	809/99	CI	ONT:HNT	+	-	-
46	826/99	CI	ONT:HNT	+	-	-
47	827/99	CI	ONT:HNT	-	+	72°C
48	834/99	CI	ONT:HNT	+	-	-
49	A 3473-1/98	ED	O139:H1	-	+	63°C
50	A 3621-2/98	ED	O139:H1	-	+	63°C
51	82812/99	ED	O139:H1	-	+	63°C

CI = clinical isolate

Ed = edema disease

It was in this case possible to identify all the human isolates as stx-positive, with detection only of stx₁ in 18 strains, only of stx₂ in 19 strains and of both genes in 11 strains. The three pig isolates were likewise stx₂-positive.

On use of the hybridization samples of the invention as shown in SEQ ID No. 7 and 8, differences in the melting temperatures of stxA2 were measured in different isolates: melting temperatures of 71-72°C were found for stxA2 in amplicons of 18 of the 30 stxA2-containing human isolates. This temperature is identical to the T_m found in preceding

04-12-2001

EP0009356

- 20 -

It was in this case possible to identify all the human isolates as stx-positive, with detection only of stx1 in 18 strains, only of stx2 in 19 strains and of both genes in 11 strains. The three pig isolates were likewise stx2-positive.

On use of the hybridization samples of the invention as shown in SEQ ID No. 7 and 8, differences in the melting temperatures of stxA2 were measured in different isolates: melting temperatures of 71-72°C were found for stxA2 in amplicons of 18 of the 30 stxA2-containing human isolates. This temperature is identical to the T_m found in preceding experiments for cloned stxA2 DNA from human-pathogenic strains. Melting temperatures of about 63°C were found for

REPLACEMENT SHEET

Table 2: Bacterial isolates tested in the specificity test		
<i>Aeromonas hydrophilia</i>		CLINICAL ISOLATE
<i>Bacillus subtilis</i>		ATCC 6633
<i>Bacillus subtilis</i>		ATCC 6051
<i>Campylobacter coli</i>		CLINICAL ISOLATE
<i>Campylobacter jejuni</i>		ATCC 33560
<i>Candida albicans</i>		ATCC 10231 Type 3
<i>Citrobacter freundii</i>		CLINICAL ISOLATE
<i>Enterobacter cloacae</i>		CLINICAL ISOLATE
<i>Enterococcus faecalis</i>		ATCC 10541
<i>Enterococcus faecalis</i>		CLINICAL ISOLATE
<i>Enterococcus faecium</i>		ATCC 19434
<i>Enterococcus faecium</i>		CLINICAL ISOLATE
<i>Escherichia coli</i>		ATCC 25922
EAEC	O-42	CLINICAL ISOLATE
EIEC	460858	CLINICAL ISOLATE
EPEC	E 2348/69	CLINICAL ISOLATE
ETEC		CLINICAL ISOLATE
<i>Helicobacter pylori</i>		CLINICAL ISOLATE
<i>Klebsiella pneumoniae</i>		ATCC 10031
<i>Morganella morganii</i>		CLINICAL ISOLATE
<i>Plesiomonas shigelloides</i>		CLINICAL ISOLATE
<i>Proteus mirabilis</i>		ATCC 1453
<i>Proteus vulgaris</i>		CLINICAL ISOLATE
<i>Pasteurella canis</i>		CLINICAL ISOLATE
<i>Pseudomonas aeruginosa</i>		ATCC 27853
<i>Salmonella enteritidis</i>		CLINICAL ISOLATE
<i>Salmonella typhimurium</i>		CLINICAL ISOLATE
<i>Shigella flexneri</i>		CLINICAL ISOLATE
<i>Staphylococcus aureus</i>		CLINICAL ISOLATE
<i>Staphylococcus epidermidis</i>		ATCC 12228
<i>Streptococcus agalactiae</i>		CLINICAL ISOLATE
<i>Yersinia enterocolitica</i>		CLINICAL ISOLATE

This example thus shows that the method of the invention is suitable for specific detection of EHEC infections.

- 22 -

SEQUENCE LISTING

<110> Roche Diagnostics Gmbh

<120> Multiplex PCR for detecting EHEC infections

<130> 529800da

<140>

<141>

<160> 8

<170> PatentIn Ver 2.1

<210> 1

<211> 24

<212> DNA

<213> Escherichia coli

<400> 1

agtcgtacgg ggatgcagat aaat

24

<210> 2

<211> 24

<212> DNA

<213> Escherichia coli

<400> 2

ccggacacat agaaggaaac tcac

24

<210> 3

<211> 20

<212> DNA

<213> Escherichia coli

<400> 3

ttccggaatg caaatcagtc

20

<210> 4

<211> 21

<212> DNA

<213> Escherichia coli

<400> 4

cgatactccg gaagcacatt g

21

- 23 -

<210> 5
<211> 30
<212> DNA
<213> Escherichia coli

<400> 5
ctgtcacagt aacaaaccgt aacatcgctc 30

<210> 6
<211> 24
<212> DNA
<213> Escherichia coli }

<400> 6
tgccacagac tgcgtcagtg aggt 24

<210> 7
<211> 28
<212> DNA
<213> Escherichia coli

<400> 7
agagcagttc tgcgttttgt cactgtca 28

<210> 8
<211> 23
<212> DNA
<213> Escherichia coli

<400> 8
agcagaagcc ttacgcttca ggc 23

04-12-2001

EP0009356

- 24 -

Cytonet GmbH & Co. KG

PCT/EP00/09356

Claims

1. Primers with a length of 17 to 25 nucleotides, whose sequences are identical to a sequence as shown in SEQ ID No. 1-4, or whose sequences represent part-sequences of one of the sequences as shown in SEQ ID No. 1-4, or in which a sequence as shown in SEQ ID No. 1-4 forms a continuous part-sequence of the primer.
2. A multiplex amplification reaction for detecting clinically relevant EHEC infections, in which both stxA1 and stxA2 sequences of both human-pathogenic and swine-pathogenic stx2 isoforms are amplified, characterized in that all of the primers as claimed in claim 1 are used.
3. The use of primers as claimed in claim 1 for detecting an EHEC infection.
4. A method as claimed in claim 2 or 3, characterized in that the product of the amplification reaction is additionally detected by hybridization.
5. The method as claimed in claim 4, characterized in that a hybridization probe has a sequence which is identical or complementary to the region which codes for the enzymatically active site of the polypeptide chain encoded by the stxA1 gene or the stxA2 gene.
6. The method as claimed in claim 2-5, characterized in that the amplification product is detected with the aid of fluorescence detection.

REPLACEMENT SHEET

ART 34 AMDT

04-12-2001

EP0009356

- 25 -

7. The method as claimed in claim 6, characterized in that the amplification product is detected with the aid of a compound which fluoresces on binding to double-stranded DNA.

8. The method as claimed in claim 4-6, characterized in that the amplification product is detected with the aid of fluorescence resonance energy transfer.

9. The method as claimed in claim 8, in which there is use of an internal standard which differs from the stxA1 or the stxA2 sequence only in one or two point mutations, characterized in that amplified target DNA and internal standard are distinguished from one another by means of a melting curve analysis.

10. The method as claimed in claim 8 or 9, characterized in that human-pathogenic stxA2 and swine-pathogenic stxA2_e are distinguished by means of a melting curve analysis.

11. Hybridization probes having sequences or part-sequences as shown in SEQ ID No. 5-8.

12. A hybridization probe having the sequence as shown in SEQ ID No. 8.

13. The method as claimed in claim 9 or 10, characterized in that hybridization probes with sequences as given in claim 11 or 12 are used.

14. Use of hybridization probes as claimed in claim 11 or 12 for determining melting curves.

15. A kit for detecting clinically relevant EHEC infections, comprising primers as claimed in claim 1.

REPLACEMENT SHEET

ART 34 AADT

04-12-2001

EP0009356

- 26 -

16. A kit as claimed in claim 15, comprising hybridization probes.

17. A kit as claimed in claim 15 or 16, comprising reagents for amplifying additional pathogenicity factors.

10089437 091202
(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
5. April 2001 (05.04.2001)

PCT

(10) Internationale Veröffentlichungsnummer
WO 01/23607 A2

- (51) Internationale Patentklassifikation⁷: C12Q 1/68 (81) Bestimmungsstaaten (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) Internationales Aktenzeichen: PCT/EP00/09356
- (22) Internationales Anmeldedatum: 26. September 2000 (26.09.2000) ✓
- (25) Einreichungssprache: Deutsch ✓
- (26) Veröffentlichungssprache: Deutsch
- (30) Angaben zur Priorität: 199 46 296.8 ✓ 28. September 1999 (28.09.1999) ✓ DE
- (71) Anmelder (*für alle Bestimmungsstaaten mit Ausnahme von US*): ROCHE DIAGNOSTICS GMBH [DE/DE]; 68298 Mannheim (DE).
- (72) Erfinder; und
- (75) Erfinder/Anmelder (*nur für US*): GUNZER, Florian [DE/DE]; Tiergartenstrasse 60, 30559 Hannover (DE). BELLIN, Tobias [DE/DE]; Klewertweg 62, 30966 Hemmingen (DE).
- (74) Gemeinsamer Vertreter: ROCHE DIAGNOSTICS GMBH; Patentabteilung, 82372 Penzberg (DE).
- (84) Bestimmungsstaaten (*regional*): ¹ARIPO-Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), ²eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ³europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), ⁴OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Veröffentlicht:
— Ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts.
- Zur Erklärung der Zweibuchstaben-Codes, und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen

(54) Title: MULTIPLEX PCR FOR DETECTING EHEC INFECTIONS


(54) Bezeichnung: MULTIPLEX-PCR ZUM NACHWEIS VON EHEC-INFEKTIONEN ✓

(57) Abstract: The invention relates to a method for detecting clinically relevant EHEC infections by amplifying both stxA1 and stxA2 sequences in a multiplex amplification reaction. The inventive method is further characterized in that both sequences of human-pathogenic and sequences of porcine-pathogenic stxA2 isoforms are amplified with the primers derived from a specific region of the stxA2 gene.


(57) Zusammenfassung: Die vorliegende Erfindung betrifft ein Verfahren zum Nachweis von klinisch relevanten EHEC-Infektionen, bei dem durch eine Multiplex-Amplifikationsreaktion sowohl stxA1 als auch stxA2 Sequenzen amplifiziert werden. Das Verfahren zeichnet sich insbesondere dadurch aus, daß sowohl Sequenzen Human-pathogener als auch Sequenzen Schweine-pathogener stxA2 Isoformen mit Primern aus einer bestimmten Region des stxA2 Gens amplifiziert werden.







WO 01/23607 A2

1/2 Fig. 1



2/2 Fig. 2



UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION		OFGS FILE NO P/2107-210																																															
<p>As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled</p> <p>MULTIPLEX PCR FOR DETECTING EHEC INFECTIONS</p>																																																	
<p>the specification of which is attached hereto, unless the following box is checked</p> <p><input checked="" type="checkbox"/> was filed on <u>26 September 2000</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP00/09356</u> and was amended on <u>4 December 2001</u> (if any).</p> <p>I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above</p> <p>I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.</p> <p>I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed</p> <p>Prior Foreign or Provisional Application(s)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">COUNTRY</th> <th style="width: 25%;">APPLICATION NUMBER</th> <th style="width: 25%;">DATE OF FILING (day, month, year)</th> <th style="width: 25%;">PRIORITY CLAIMED UNDER 35 U.S.C. 119</th> </tr> </thead> <tbody> <tr> <td>Germany</td> <td>199 46 296.8</td> <td>28 September 1999</td> <td>YES <u>X</u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> </tbody> </table> <p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">UNITED STATES APPLICATION NUMBER</th> <th style="width: 30%;">DATE OF FILING (day, month, year)</th> <th style="width: 40%;">STATUS (patented, pending, abandoned)</th> </tr> </thead> <tbody> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> </tbody> </table> <p>I hereby appoint customer no 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP, and the members of the firm, Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Faber - Reg. No. 24,322; Max Moskowitz - Reg. No. 30,576; James A. Finder - Reg. No. 30,173; William O. Gray, III - Reg. No. 30,944; Louis C. Dujmich - Reg. No. 30,625, and Douglas A. Miro - Reg. No. 31,643, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence</p> <p>SEND CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP DIRECT TELEPHONE CALLS TO: 1180 AVENUE OF THE AMERICAS (212) 382-0700 NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">FULL NAME OF SOLE OR FIRST INVENTOR Florian GUNZER</td> <td style="width: 30%;">INVENTOR'S SIGNATURE </td> <td style="width: 30%;">DATE 14.05.02</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) 30559 Hannover, Germany</td> <td>COUNTRY OF CITIZENSHIP Germany</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS Tiergartenstrasse 60, 30559 Hannover, Germany</td> </tr> <tr> <td>FULL NAME OF SECOND JOINT INVENTOR (IF ANY) Tobias BELLIN</td> <td>INVENTOR'S SIGNATURE </td> <td>DATE 14.05.02</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) 30966 Hemmingen, Germany</td> <td>COUNTRY OF CITIZENSHIP Germany</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS Klewertweg 62, 30966 Hemmingen, Germany</td> </tr> </table>				COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119	Germany	199 46 296.8	28 September 1999	YES <u>X</u> NO <u> </u>				YES <u> </u> NO <u> </u>				YES <u> </u> NO <u> </u>	UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)										FULL NAME OF SOLE OR FIRST INVENTOR Florian GUNZER	INVENTOR'S SIGNATURE 	DATE 14.05.02	RESIDENCE (City and either State or Foreign Country) 30559 Hannover, Germany		COUNTRY OF CITIZENSHIP Germany	POST OFFICE ADDRESS Tiergartenstrasse 60, 30559 Hannover, Germany			FULL NAME OF SECOND JOINT INVENTOR (IF ANY) Tobias BELLIN	INVENTOR'S SIGNATURE 	DATE 14.05.02	RESIDENCE (City and either State or Foreign Country) 30966 Hemmingen, Germany		COUNTRY OF CITIZENSHIP Germany	POST OFFICE ADDRESS Klewertweg 62, 30966 Hemmingen, Germany		
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119																																														
Germany	199 46 296.8	28 September 1999	YES <u>X</u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)																																															
FULL NAME OF SOLE OR FIRST INVENTOR Florian GUNZER	INVENTOR'S SIGNATURE 	DATE 14.05.02																																															
RESIDENCE (City and either State or Foreign Country) 30559 Hannover, Germany		COUNTRY OF CITIZENSHIP Germany																																															
POST OFFICE ADDRESS Tiergartenstrasse 60, 30559 Hannover, Germany																																																	
FULL NAME OF SECOND JOINT INVENTOR (IF ANY) Tobias BELLIN	INVENTOR'S SIGNATURE 	DATE 14.05.02																																															
RESIDENCE (City and either State or Foreign Country) 30966 Hemmingen, Germany		COUNTRY OF CITIZENSHIP Germany																																															
POST OFFICE ADDRESS Klewertweg 62, 30966 Hemmingen, Germany																																																	

☐ CONTINUED ON PAGE 2